Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Topical 0.05% cyclosporine A eyedrops in the treatment of moderate–severe vernal keratoconjunctivitis

Poster Details

First Author: T. Ayyildiz TURKEY

Co Author(s):    K. Calisir   U. Calli                 

Abstract Details


To investigate the efficacy of topical cyclosporine A (CsA) 0.05% in patients with moderate-to-severe vernal keratoconjunctivitis (VKC).


Retrospective cohort, observational study


This retrospective study included 37 patients who were admitted to our clinic between January 2015 to December 2015. All patients were diagnosed with moderate-to-severe VKC and had topical CsA 0.05% (Restasis Allergan, Inc. Irvine, USA) treatment. VKC diagnosis was based on patient history and typical clinical signs and symptoms. Sign and symptom scores of each patient were obtained at pre-treatment and during treatment (1, 3 and 6. months).


Of the 37 patients, 20 (54.1%) were male and 17 (45.9%) were female. The mean age of the patients was 11.83±4.70 year (6-24 year). The symptom-sign scores and total scores of the patients were significantly reduced at 1, 3 and 6 month time points when compared to baseline values. Symptom-sign scores were also significantly reduced from 1 month to 3 month and from 3 month to 6 month (p<0.05).


Topical CsA 0.05% is an effective formulation that is used in the treatment of moderate-to-severe VK patients and it may reduce need for steroids.

Financial Disclosure:


Back to Poster listing